The effect of lipoproteins on the development and progression of renal disease

被引:48
作者
Dalrymple, Lorien S. [1 ]
Kaysen, George A. [1 ,2 ,3 ]
机构
[1] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA
[3] Dept Vet Affairs No Calif Hlth Care Syst, Dept Med, Sacramento, CA USA
关键词
lipids; chronic kidney disease; nephropathy; progression; statins;
D O I
10.1159/000127980
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The field of research examining how lipoproteins may contribute to the development and/or progression of renal disease has rapidly expanded over the last 25 years. In animal models, lipoproteins and lipids have been associated with both the initiation and progression of renal disease. Numerous potential mechanisms of lipoprotein-induced renal injury have been identified by utilizing animal models and tissue-culture experiments. However, with the exception of rare genetic mutations, the association between lipoproteins and human renal disease is less clear. In humans, the evidence that lipid-lowering therapy delays renal progression is limited. The purpose of this paper is to review the current literature on lipoprotein abnormalities and the development or progression of renal disease. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:723 / 731
页数:9
相关论文
共 64 条
  • [31] The role of lipids in renal disease: Future challenges
    Keane, WF
    [J]. KIDNEY INTERNATIONAL, 2000, 57 : S27 - S31
  • [32] KEANE WF, 1991, KIDNEY INT, V39, pS41
  • [33] KEANE WF, 1993, J AM SOC NEPHROL, V4, P187
  • [34] Very low-density lipoprotein stimulates the expression of monocyte chemoattractant protein-1 in mesangial cells
    Lynn, EG
    Siow, YL
    O, K
    [J]. KIDNEY INTERNATIONAL, 2000, 57 (04) : 1472 - 1483
  • [35] Magil AB, 1999, MODERN PATHOL, V12, P33
  • [36] OXIDIZED LOW-DENSITY-LIPOPROTEIN IN EXPERIMENTAL FOCAL GLOMERULOSCLEROSIS
    MAGIL, AB
    FROHLICH, JJ
    INNIS, SM
    STEINBRECHER, UP
    [J]. KIDNEY INTERNATIONAL, 1993, 43 (06) : 1243 - 1250
  • [37] Dyslipidaemia and the progression of renal disease in chronic renal failure patients
    Massy, ZA
    Khoa, TN
    Lacour, B
    Descamps-Latscha, B
    Man, NK
    Jungers, P
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (10) : 2392 - 2397
  • [38] A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy
    Matsunaga, A
    Sasaki, J
    Komatsu, T
    Kanatsu, K
    Tsuji, E
    Moriyama, K
    Koga, T
    Arakawa, K
    Oikawa, S
    Saito, T
    Kita, T
    Doi, T
    [J]. KIDNEY INTERNATIONAL, 1999, 56 (02) : 421 - 427
  • [39] MOORHEAD JF, 1982, LANCET, V2, P1309
  • [40] Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study
    Muntner, P
    Coresh, J
    Smith, JC
    Eckfeldt, J
    Klag, MJ
    [J]. KIDNEY INTERNATIONAL, 2000, 58 (01) : 293 - 301